GlassScriptPhysician profile
Mark Laurence Shiu
NPI 1629004478
$18,000.87
in general payments reported to CMS, 2019-2025
69 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,940 · 2020: $2,855 · 2021: $3,441 · 2022: $4,407 · 2023: $1,463 · 2024: $1,592 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.74 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,298.94 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,001.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,548.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,430.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,070.10 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Abbott Laboratories | $712.22 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $621.92 | 2019-2024 | Xifaxan |
| Antares Pharma, INC. | $589.06 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $547.26 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $502.22 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Lilly USA, LLC | $495.38 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $462.93 | 2019-2023 | |
| Esperion Therapeutics, INC. | $403.31 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $397.74 | 2019-2023 | Trintellix |
| Allergan, INC. | $386.21 | 2019-2021 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.